(Q34804758)

4 August 2017

1 reference

title

Resistance in the land of molecular cancer therapeutics (English)

1 reference

4 August 2017

Kevin M Shannon

1

1 reference

4 August 2017

publication date

1 August 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

2

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

99-102

1 reference

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Perspectives on the development of a molecularly targeted agent

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Reversible tumorigenesis by MYC in hematopoietic lineages

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Reversibility of acute B-cell leukaemia induced by BCR-ABL1.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Ras processing as a therapeutic target in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

1 reference

7 January 2021

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Pathogenesis and management of acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900101-0

7 January 2021

10.1016/S1535-6108(02)00101-0

Identifiers

DOI

1 reference

4 August 2017

1 reference